Gabelli Funds LLC Has $6.69 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Gabelli Funds LLC increased its stake in Teva Pharmaceutical Industries by 18.4%, owning 435,075 shares valued at approximately $6.69 million as of the latest SEC filing.
• Several institutional investors, including Golden State Wealth Management and Brooklyn Investment Group, also bought new stakes in Teva Pharmaceuticals, indicating growing institutional interest.
• Teva's recent financial performance included an earnings report with $0.66 EPS, surpassing estimates, and analysts maintaining a consensus rating of "Buy" with a price target averaging $24.71.

Gabelli Funds LLC grew its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 18.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 435,075 shares of the company's stock after purchasing an additional 67,575 shares during the period. Gabelli Funds LLC's holdings in Teva Pharmaceutical Industries were worth $6,687,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Jump Financial LLC raised its position in Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 5.7% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock worth $38,487,000 after acquiring an additional 134,705 shares in the last quarter. Financial Sense Advisors Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 63.5% in the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after purchasing an additional 157,421 shares during the last quarter. King Wealth Management Group lifted its position in shares of Teva Pharmaceutical Industries by 1,106.9% in the first quarter. King Wealth Management Group now owns 175,000 shares of the company's stock worth $2,690,000 after purchasing an additional 160,500 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock valued at $1,037,000 after buying an additional 60,016 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Truist Financial started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.37 during midday trading on Monday, reaching $18.41. The company's stock had a trading volume of 7,153,308 shares, compared to its average volume of 10,852,338. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The stock has a market cap of $21.11 billion, a PE ratio of -115.04, a price-to-earnings-growth ratio of 1.09 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The business has a 50-day moving average price of $16.86 and a 200-day moving average price of $16.32.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm's quarterly revenue was up .3% compared to the same quarter last year. During the same period last year, the company posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,001 shares of company stock valued at $996,958. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.